Aerpio Pharmaceuticals to Present at the 20th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC
Aug. 30, 2018
CINCINNATI--(BUSINESS WIRE)--Aug 30, 2018--Aerpio Pharmaceuticals, Inc. (Nasdaq:ARPO), a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases, today announced that Chief Executive Officer, Stephen Hoffman, M.D., Ph.D., will present at the 20 th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC, on Thursday, September 6, 2018 at 10:00 a.m. Eastern Time in New York, NY. Dr. Hoffman will provide a corporate overview and business update.
The presentation will be webcast live and may be accessed by visiting Aerpio's website at http://ir.aerpio.com/.
About Aerpio Pharmaceuticals
Aerpio Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases. The Company’s lead compound, AKB-9778, is a small molecule activator of the Tie2 pathway and is in clinical development for the treatment of non-proliferative diabetic retinopathy. For more information, please visit www.aerpio.com.
View source version on businesswire.com:https://www.businesswire.com/news/home/20180830005087/en/
CONTACT: Investor & Media:
Aerpio Pharmaceuticals, Inc.
Chief Financial Officer
Burns McClellan, on behalf of Aerpio Pharmaceuticals, Inc.
Robert Flamm, Ph.D.
KEYWORD: UNITED STATES NORTH AMERICA NEW YORK OHIO
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY OPTICAL PHARMACEUTICAL DIABETES
SOURCE: Aerpio Pharmaceuticals, Inc.
Copyright Business Wire 2018.
PUB: 08/30/2018 07:00 AM/DISC: 08/30/2018 07:01 AM